Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS). 166 patients with relap...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2021-12, Vol.163 (3), p.598-604 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 604 |
|---|---|
| container_issue | 3 |
| container_start_page | 598 |
| container_title | Gynecologic oncology |
| container_volume | 163 |
| creator | Gernier, F. Gompel, A. Rousset-Jablonski, C. Kalbacher, E. Floquet, A. Berton-Rigaud, D. Tredan, O. Alexandre, J. Follana, P. Zannetti, A. Dohollou, N. Grellard, J.-M. Clarisse, B. Licaj, I. Ahmed-Lecheheb, D. Fauvet, R. Pautier, P. Joly, F. |
| description | We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).
166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM).
Mean age at the survey was 62 [21–83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P |
| doi_str_mv | 10.1016/j.ygyno.2021.10.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_crist</sourceid><recordid>TN_cdi_cristin_nora_10037_24155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825821014190</els_id><sourcerecordid>2582815899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-cb856359fdbc232600f4268e3e68eb59b20f7292a76ccdfe2fb6d9fe6f5a9a203</originalsourceid><addsrcrecordid>eNp9kNFq2zAUhkXZaLOuT1Boddkbp5JsKdZgFyFkXaBboGy5FbJ81CrYlifZAb_9lKXdZW8k-PnOfzgfQteUzCmh4n4_n56nzs8ZYTQlc0LoGZpRInkmSi4_oBkhkmQl4-UF-hTjnhCSE8rO0UVeiEIuWDFDux_Q-V6PUTc4Tm0_-DZi12Ho3fACjUuxP-jgdIeN7gwEHMdwcAcf4hes8cPm53q1xbvN7mm7W26e1gzHYaynz-ij1U2Eq9f_Ev3-tv61-p49bh82q-VjZgpWDpmpSi5yLm1dGZYzQYgtmCghh_RUXFaM2AWTTC-EMbUFZitRSwvCci01I_kluj31muDi4DrV-aAVTYcuFCso54m4OxF98H9GiINqXTTQNLoDP0aV7LCS8lLKhOZvZT7GAFb1wbU6TKlQHZWrvfqnXB2VH8OkPE3dvC4Yqxbq_zNvjhPw9QRAEnFwEFQ0DpLL2gUwg6q9e3fBX295ka8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582815899</pqid></control><display><type>article</type><title>Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Elsevier ScienceDirect Journals</source><creator>Gernier, F. ; Gompel, A. ; Rousset-Jablonski, C. ; Kalbacher, E. ; Floquet, A. ; Berton-Rigaud, D. ; Tredan, O. ; Alexandre, J. ; Follana, P. ; Zannetti, A. ; Dohollou, N. ; Grellard, J.-M. ; Clarisse, B. ; Licaj, I. ; Ahmed-Lecheheb, D. ; Fauvet, R. ; Pautier, P. ; Joly, F.</creator><creatorcontrib>Gernier, F. ; Gompel, A. ; Rousset-Jablonski, C. ; Kalbacher, E. ; Floquet, A. ; Berton-Rigaud, D. ; Tredan, O. ; Alexandre, J. ; Follana, P. ; Zannetti, A. ; Dohollou, N. ; Grellard, J.-M. ; Clarisse, B. ; Licaj, I. ; Ahmed-Lecheheb, D. ; Fauvet, R. ; Pautier, P. ; Joly, F.</creatorcontrib><description>We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).
166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM).
Mean age at the survey was 62 [21–83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT).
VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.
•≥3 years after treatment, more than half of epithelial ovarian cancer survivors EOCS had vasomotor symptoms.•Two thirds of the EOCS reported a decrease in libido and, 1/3 sexually active EOCS complained of dyspareunia.•EOCS with surgical menopause reported more vasomotor symptoms and sexual disorders than those with natural menopause.•Very few patients received hormone replacement therapy after cancer treatment.</description><identifier>ISSN: 0090-8258</identifier><identifier>ISSN: 1095-6859</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2021.10.001</identifier><identifier>PMID: 34649724</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Cancer Survivors ; Carcinoma, Ovarian Epithelial - physiopathology ; Carcinoma, Ovarian Epithelial - surgery ; Case-Control Studies ; Epithelial ovarian cancer ; Female ; Hormone replacement therapy ; Humans ; Long-term survivorship ; Menopause ; Menopause - physiology ; Middle Aged ; Ovarian Neoplasms - physiopathology ; Ovarian Neoplasms - surgery ; Quality of Life ; Sexuality ; Sociodemographic Factors ; Vasomotor symptoms ; Vasomotor System - physiopathology ; Young Adult</subject><ispartof>Gynecologic oncology, 2021-12, Vol.163 (3), p.598-604</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-cb856359fdbc232600f4268e3e68eb59b20f7292a76ccdfe2fb6d9fe6f5a9a203</citedby><cites>FETCH-LOGICAL-c428t-cb856359fdbc232600f4268e3e68eb59b20f7292a76ccdfe2fb6d9fe6f5a9a203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825821014190$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3536,26545,27902,27903,65308</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34649724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gernier, F.</creatorcontrib><creatorcontrib>Gompel, A.</creatorcontrib><creatorcontrib>Rousset-Jablonski, C.</creatorcontrib><creatorcontrib>Kalbacher, E.</creatorcontrib><creatorcontrib>Floquet, A.</creatorcontrib><creatorcontrib>Berton-Rigaud, D.</creatorcontrib><creatorcontrib>Tredan, O.</creatorcontrib><creatorcontrib>Alexandre, J.</creatorcontrib><creatorcontrib>Follana, P.</creatorcontrib><creatorcontrib>Zannetti, A.</creatorcontrib><creatorcontrib>Dohollou, N.</creatorcontrib><creatorcontrib>Grellard, J.-M.</creatorcontrib><creatorcontrib>Clarisse, B.</creatorcontrib><creatorcontrib>Licaj, I.</creatorcontrib><creatorcontrib>Ahmed-Lecheheb, D.</creatorcontrib><creatorcontrib>Fauvet, R.</creatorcontrib><creatorcontrib>Pautier, P.</creatorcontrib><creatorcontrib>Joly, F.</creatorcontrib><title>Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).
166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM).
Mean age at the survey was 62 [21–83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT).
VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.
•≥3 years after treatment, more than half of epithelial ovarian cancer survivors EOCS had vasomotor symptoms.•Two thirds of the EOCS reported a decrease in libido and, 1/3 sexually active EOCS complained of dyspareunia.•EOCS with surgical menopause reported more vasomotor symptoms and sexual disorders than those with natural menopause.•Very few patients received hormone replacement therapy after cancer treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer Survivors</subject><subject>Carcinoma, Ovarian Epithelial - physiopathology</subject><subject>Carcinoma, Ovarian Epithelial - surgery</subject><subject>Case-Control Studies</subject><subject>Epithelial ovarian cancer</subject><subject>Female</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Long-term survivorship</subject><subject>Menopause</subject><subject>Menopause - physiology</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - physiopathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Quality of Life</subject><subject>Sexuality</subject><subject>Sociodemographic Factors</subject><subject>Vasomotor symptoms</subject><subject>Vasomotor System - physiopathology</subject><subject>Young Adult</subject><issn>0090-8258</issn><issn>1095-6859</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNp9kNFq2zAUhkXZaLOuT1Boddkbp5JsKdZgFyFkXaBboGy5FbJ81CrYlifZAb_9lKXdZW8k-PnOfzgfQteUzCmh4n4_n56nzs8ZYTQlc0LoGZpRInkmSi4_oBkhkmQl4-UF-hTjnhCSE8rO0UVeiEIuWDFDux_Q-V6PUTc4Tm0_-DZi12Ho3fACjUuxP-jgdIeN7gwEHMdwcAcf4hes8cPm53q1xbvN7mm7W26e1gzHYaynz-ij1U2Eq9f_Ev3-tv61-p49bh82q-VjZgpWDpmpSi5yLm1dGZYzQYgtmCghh_RUXFaM2AWTTC-EMbUFZitRSwvCci01I_kluj31muDi4DrV-aAVTYcuFCso54m4OxF98H9GiINqXTTQNLoDP0aV7LCS8lLKhOZvZT7GAFb1wbU6TKlQHZWrvfqnXB2VH8OkPE3dvC4Yqxbq_zNvjhPw9QRAEnFwEFQ0DpLL2gUwg6q9e3fBX295ka8</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Gernier, F.</creator><creator>Gompel, A.</creator><creator>Rousset-Jablonski, C.</creator><creator>Kalbacher, E.</creator><creator>Floquet, A.</creator><creator>Berton-Rigaud, D.</creator><creator>Tredan, O.</creator><creator>Alexandre, J.</creator><creator>Follana, P.</creator><creator>Zannetti, A.</creator><creator>Dohollou, N.</creator><creator>Grellard, J.-M.</creator><creator>Clarisse, B.</creator><creator>Licaj, I.</creator><creator>Ahmed-Lecheheb, D.</creator><creator>Fauvet, R.</creator><creator>Pautier, P.</creator><creator>Joly, F.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>3HK</scope></search><sort><creationdate>20211201</creationdate><title>Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study</title><author>Gernier, F. ; Gompel, A. ; Rousset-Jablonski, C. ; Kalbacher, E. ; Floquet, A. ; Berton-Rigaud, D. ; Tredan, O. ; Alexandre, J. ; Follana, P. ; Zannetti, A. ; Dohollou, N. ; Grellard, J.-M. ; Clarisse, B. ; Licaj, I. ; Ahmed-Lecheheb, D. ; Fauvet, R. ; Pautier, P. ; Joly, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-cb856359fdbc232600f4268e3e68eb59b20f7292a76ccdfe2fb6d9fe6f5a9a203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer Survivors</topic><topic>Carcinoma, Ovarian Epithelial - physiopathology</topic><topic>Carcinoma, Ovarian Epithelial - surgery</topic><topic>Case-Control Studies</topic><topic>Epithelial ovarian cancer</topic><topic>Female</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Long-term survivorship</topic><topic>Menopause</topic><topic>Menopause - physiology</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - physiopathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Quality of Life</topic><topic>Sexuality</topic><topic>Sociodemographic Factors</topic><topic>Vasomotor symptoms</topic><topic>Vasomotor System - physiopathology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gernier, F.</creatorcontrib><creatorcontrib>Gompel, A.</creatorcontrib><creatorcontrib>Rousset-Jablonski, C.</creatorcontrib><creatorcontrib>Kalbacher, E.</creatorcontrib><creatorcontrib>Floquet, A.</creatorcontrib><creatorcontrib>Berton-Rigaud, D.</creatorcontrib><creatorcontrib>Tredan, O.</creatorcontrib><creatorcontrib>Alexandre, J.</creatorcontrib><creatorcontrib>Follana, P.</creatorcontrib><creatorcontrib>Zannetti, A.</creatorcontrib><creatorcontrib>Dohollou, N.</creatorcontrib><creatorcontrib>Grellard, J.-M.</creatorcontrib><creatorcontrib>Clarisse, B.</creatorcontrib><creatorcontrib>Licaj, I.</creatorcontrib><creatorcontrib>Ahmed-Lecheheb, D.</creatorcontrib><creatorcontrib>Fauvet, R.</creatorcontrib><creatorcontrib>Pautier, P.</creatorcontrib><creatorcontrib>Joly, F.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gernier, F.</au><au>Gompel, A.</au><au>Rousset-Jablonski, C.</au><au>Kalbacher, E.</au><au>Floquet, A.</au><au>Berton-Rigaud, D.</au><au>Tredan, O.</au><au>Alexandre, J.</au><au>Follana, P.</au><au>Zannetti, A.</au><au>Dohollou, N.</au><au>Grellard, J.-M.</au><au>Clarisse, B.</au><au>Licaj, I.</au><au>Ahmed-Lecheheb, D.</au><au>Fauvet, R.</au><au>Pautier, P.</au><au>Joly, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>163</volume><issue>3</issue><spage>598</spage><epage>604</epage><pages>598-604</pages><issn>0090-8258</issn><issn>1095-6859</issn><eissn>1095-6859</eissn><abstract>We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).
166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM).
Mean age at the survey was 62 [21–83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT).
VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.
•≥3 years after treatment, more than half of epithelial ovarian cancer survivors EOCS had vasomotor symptoms.•Two thirds of the EOCS reported a decrease in libido and, 1/3 sexually active EOCS complained of dyspareunia.•EOCS with surgical menopause reported more vasomotor symptoms and sexual disorders than those with natural menopause.•Very few patients received hormone replacement therapy after cancer treatment.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34649724</pmid><doi>10.1016/j.ygyno.2021.10.001</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2021-12, Vol.163 (3), p.598-604 |
| issn | 0090-8258 1095-6859 1095-6859 |
| language | eng |
| recordid | cdi_cristin_nora_10037_24155 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Cancer Survivors Carcinoma, Ovarian Epithelial - physiopathology Carcinoma, Ovarian Epithelial - surgery Case-Control Studies Epithelial ovarian cancer Female Hormone replacement therapy Humans Long-term survivorship Menopause Menopause - physiology Middle Aged Ovarian Neoplasms - physiopathology Ovarian Neoplasms - surgery Quality of Life Sexuality Sociodemographic Factors Vasomotor symptoms Vasomotor System - physiopathology Young Adult |
| title | Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T09%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Menopausal%20symptoms%20in%20epithelial%20ovarian%20cancer%20survivors:%20a%20GINECO%20VIVROVAIRE2%20study&rft.jtitle=Gynecologic%20oncology&rft.au=Gernier,%20F.&rft.date=2021-12-01&rft.volume=163&rft.issue=3&rft.spage=598&rft.epage=604&rft.pages=598-604&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2021.10.001&rft_dat=%3Cproquest_crist%3E2582815899%3C/proquest_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2582815899&rft_id=info:pmid/34649724&rft_els_id=S0090825821014190&rfr_iscdi=true |